Relative decreases in VP mean weights using VIN against TP controls in eight laboratories (Lab) by William Owens (20777)

Effect of 5-min photostimulation of hippocampal CA1 astrocytes on learning, LCN2 protein, and hippocampal LTP. by Jae-Hong Kim (124622)

Five compounds significantly decrease MAPK1 phosphorylation in K562 cells. by Pamela Y. Ting (713174)

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

LY5 does not inhibit growth of <i>ex vivo</i> pulmonary metastasis. by Peter Y. Yu (4281448)

Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

Assays of TUNEL revealed a decreased number of apoptotic cell after oroxylin A treatment. by Shu-Fang Lin (4167091)

Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months. by Allyson J. Gallant (9382396)

Mitochondrial dysfunction is driven by decreased mitochondrial dynamics. by Piero Dalle Pezze (622889)

“…These perturbations affected the new mitochondria only at early time points (<10 days), whereas the old mitochondria were affected throughout the time course. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects: